Table 1 Summary of major clinical trials on aerosol measles vaccines presented to the expert group for stage II of the CHNRI process
Reference | MV Strain | Age group | Seroconversion as defined by authors |
|---|---|---|---|
A.Dilraj et al [46] | MV-Schwarz ( s/c, aerosol), MV- Edmonston-Zagreb ( s/c, aerosol) | 992 participants 5-14 years | Seroconversion rates (defined as four fold increase in antibody level): EZ Aerosol 鈥� 84.7% EZ sc 鈥� 78.8% SW Aerosol 鈥� 22.7% SW sc 鈥� 62.6% |
A.Dilraj et al [47] | MV-Schwarz ( s/c), MV- Edmonston-Zagreb ( s/c, aerosol) | 337 participants 5-14 years | Seroconversion (defined as four fold increase in antibody level) at 6 years after revaccination: EZ Aerosol 鈥� 86% EZ sc 鈥� 73% SW sc 鈥� 58% |
J.A.Bellanti et al [48] | MV- Edmonston-Zagreb ( s/c, aerosol) | 49 participants 6-7 years | The mean Specific anti-measles IgG antibody: EZ sc - 22.9 卤 4.6 EZ aerosol - 53.4 卤 9.4 Results are reported as mean _ 碌g/ml 卤 standard error of the mean |
J.V.Bennett et al [49] | MV-Schwarz ( s/c), MV- Edmonston-Zagreb ( s/c, aerosol) | 1624 participants 6-8 years | Change from seronegative to seropositive, >= 120 mIU/ml EZ aerosol 鈥� 65% EZ sc 鈥� 4% SW sc 鈥� 23% |
R.M.Wong-Chew et al [50] | MV- Edmonston-Zagreb ( s/c, aerosol) | 114 participants 11-13 months | Seroresponse rates as defined by four fold increase in antibody level: EZ aerosol 鈥� 89.8% EZ sc 鈥� 100% |
R.M.Wong-Chew et al [51] | MV- Edmonston-Zagreb ( s/c, aerosol) | 129 participants 8-10 months | Seroresponse rates as defined by four fold increase in antibody level: EZ Aerosol 鈥� 42% EZ sc 鈥� 67% |